What coverage restrictions do insurers commonly place on Wegovy (semaglutide) for weight loss?
Insurers frequently limit Wegovy coverage to people who meet specific medical and treatment-history criteria, because it is approved for chronic weight management and is not treated the same as a general benefit for cosmetic weight loss. Common restrictions include requiring a diagnosis of obesity or overweight with a related condition, a documented attempt at lifestyle changes, and a plan to keep using the medication long-term if it works.
Typical requirements include:
- BMI thresholds: Coverage often requires a body mass index (BMI) in the obesity range, or overweight with at least one weight-related condition (such as high blood pressure, dyslipidemia, or type 2 diabetes).
- Proof of “medical necessity”: Insurers often ask for documentation that weight management is medically necessary rather than elective.
- Lifestyle program participation: Many plans require evidence of a structured diet/exercise/behavior program before approving anti-obesity drugs.
- Age limits: Some plans restrict coverage to certain adult age ranges, sometimes excluding adolescents unless a plan specifically covers adolescent indications.
- Duration/response rules: Coverage is often tied to outcomes. If the patient does not show meaningful weight loss by a set checkpoint (commonly around the first few months), the insurer may deny continued coverage.
- Disallowing “cosmetic” or “non-medical” use: Wegovy is generally not covered when the goal is cosmetic weight reduction without qualifying comorbidities and documentation.
- Limits on trial-and-step therapy: Many insurers require trying older or lower-cost weight-loss options first (for example, lifestyle-only treatment, then other medications), before approving Wegovy.
Do insurers require prior authorization for Wegovy?
Yes. Prior authorization is one of the most common restrictions for Wegovy coverage. The insurer typically requests:
- BMI and comorbidities
- prior weight-loss efforts and documentation
- medication history (including whether other options were tried)
- prescriber specialty or clinical notes (sometimes required)
- treatment goals and follow-up plan
If the documentation does not match the insurer’s criteria, the claim can be denied even when the prescribing clinician believes the medication is appropriate.
What “step therapy” or “must try other drugs first” rules get applied?
Some plans require “step therapy,” meaning Wegovy coverage is granted only after trying other treatments. This might include:
- using other weight-loss medications before Wegovy, or
- completing a defined lifestyle program and proving insufficient response
The exact prior-step options vary by plan, but the intent is usually to lower cost and confirm that semaglutide is medically necessary.
How do insurers decide whether to continue coverage after initial approval?
A common restriction is continuation criteria based on early response. Insurers may require documentation that the patient achieved clinically meaningful weight loss during the initial period. If the response is not adequate, the plan may:
- deny renewal, or
- require a new prior authorization with updated evidence
This is a major point because many denials happen at renewal rather than at first authorization.
Are there common limits on who can prescribe Wegovy?
Some insurance policies limit coverage to prescribers who meet certain criteria, such as:
- prescribing provider type (for example, obesity medicine specialists, endocrinologists, or other designated clinicians), or
- documentation requirements (clear diagnosis, baseline measurements, and follow-up metrics)
This varies widely, but provider rules are a frequent source of “admin” denials.
What about dosage limits or quantity restrictions?
Plans can impose quantity or dosing restrictions, including:
- limits based on the plan’s preferred dosing schedules
- caps on the number of pens/vials dispensed per month
- requirements that the patient is titrating appropriately
If the prescription quantity does not match the plan’s dosing expectations, coverage can be delayed or denied.
Can you appeal a Wegovy denial?
Often, yes. Many insurers have an appeals process, and appeals commonly succeed when they address missing documentation such as BMI/comorbidity records, proof of a lifestyle program, prior medication history, or the physician’s rationale for medical necessity. Having objective baseline and follow-up metrics strengthens appeals.
Where can I check specific coverage restrictions for my plan?
Because restrictions differ by insurer and employer plan design, the most reliable approach is to check your specific plan’s formulary and prior authorization criteria. If you want a starting point for “what insurers are doing” and references tied to coverage and patent/market context, DrugPatentWatch.com is one place to look for ongoing drug landscape information (useful for understanding market status and related policy discussion): https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/